We aim to expand access to affordable, appropriate and sustainable medical technologies that address unmet health needs in the world’s most resource constrained populations.
Only a few diabetics in developing countries have the opportunity to take their insulin in an insulin pen used by those diabetics in affluent countries. Instead, they are relegated to using traditional syringes and needles, which are cheaper but difficult to use safely.
We wish to change this.
Building on a grant from the Danish “Innovationsfonden”, we seek additional support for maturing a patented concept that combines elements of known and new technology into a new, safe and cheaper type of insulin pen.
Of the world's 425 million diabetics, 300 million live in developing countries, where the incidence of diabetes is increasing at an alarming rate [IDF, 2017]. About 13 million resource poor people with diabetes buy insulin in vials. [IMS, 2017]. The vast majority cannot afford to buy insulin in the insulin pens used in most middle- and high-income countries, and health systems do not usually offer this option.
We want to partner with foundations and companies that will help create a better future for the many people who do not have access to modern medical devices, thereby contributing to the achievement of UN's World Goal 3 on improving health for all.
The GO-Pen device creates access to a new insulin pen combining established mechanisms (which it has the rights and IP to exploit) with technical innovations to develop a significantly cheaper product. The GO-Pen combines a reusable unit that accurately doses insulin held in a capsule that can be refilled from vials. This eliminates the need for syringes. The benefits are, 1) a quicker, more discrete injection, 2) fewer life-threatening hypos, 3) reduced cost of training healthcare professionals, 4) ease of use and higher adherence, 5) reduced risk of complications, 6) reduced cost; and 7) reduced hazardous waste and CO2 emissions
This device will help create a better future for the many people who do not have access to modern insulin pens.
The majority of resource poor people on insulin therapy inject with a syringe 1,2.
This decreases dosing precision, and 80% have fear of injection.
Often people injecting with syringes need help to inject.
Poor have cash flow issues and buy treatment every day.
1.8 billion syringes made of plastic is thrown out as dangerous waste yearly.
Pak Waslo, T2D
1 out of a 1.4 million buy’s insulin in Indonesia.
Pak will save money & time with this device.
Carmen Smith, T2D
1 out of 500.000 buy’s Insulin in Wallmart in the US.
Carmen will get access to a insulin pen, instead of syringe at similar price.
Teresa Sanchez, T2D
1 out of 2 million buy’s insulin in Mexico.
Teresa will be able to take her insulin, without help from her son.
GO-Pen Aps wishes to use its unique competences in insulin injection device development to improve health of resource poor people with diabetes while reducing their carbon footprint at the same price they pay today. Insulin users will have reduced their fear of injection, get better compliance, and increase their feeling of self-management.
We will reduce resource consumption of insulin injection devices by combining new and know technology that increase value creation in the entire value chain from manufacturers, distributors, to resource poor people living everyday with diabetes
We innovate with a business approach to benefit the global goals. We focus on health, sustainable growth, and climate change.